Actelion (Actelion) Other Gross PPE : $347 Mil (As of Mar. 2017)

View and export this data going back to . Start your Free Trial

What is Actelion Other Gross PPE?

Actelion's Other Gross PPE for the quarter that ended in Mar. 2017 was $347 Mil.

Actelion's quarterly Other Gross PPE declined from Sep. 2016 ($353 Mil) to Dec. 2016 ($36 Mil) but then increased from Dec. 2016 ($36 Mil) to Mar. 2017 ($347 Mil).

Actelion's annual Other Gross PPE increased from Dec. 2014 ($36 Mil) to Dec. 2015 ($36 Mil) but then declined from Dec. 2015 ($36 Mil) to Dec. 2016 ($36 Mil).

Actelion Other Gross PPE Historical Data

The historical data trend for Actelion's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actelion Other Gross PPE Chart

Actelion Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Other Gross PPE

Get a 7-Day Free Trial

31.08

33.20

36.04

36.23

35.98

Actelion Quarterly Data
	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17
Other Gross PPE	Get a 7-Day Free Trial															350.02	350.67	353.17	35.98	347.42

Actelion Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Actelion (Actelion) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actelion Ltd (OTCPK:ALIOF) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.actelion.com

Actelion is a Swiss biopharmaceutical firm with several products on the market, largely focused on pulmonary arterial hypertension: Tracleer, Opsumit, Uptravi, Ventavis, and Veletri treat various stages of the disease via different methods of administration. Zavesca is a second-line option for Gaucher disease, and Valchlor treats a rare form of blood cancer. Actelion has created a global commercial infrastructure for its approved orphan drugs and has supplemented its internal pipeline through in-licensing and acquisitions.

Actelion (Actelion) Headlines

From GuruFocus

Jean Hynes Reduces Stake in Actelion

By Kyle Ferguson Kyle Ferguson • 08-03-2016

Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary

By Holly LaFon Holly LaFon • 02-14-2017

Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary

By Holly LaFon Holly LaFon • 01-24-2017

Actelion Still On Growth Track

By reports.droy reports.droy • 02-18-2015